J-ADNI home

Japanese ADNI project  January 2011, PI Takeshi Iwatsubo, Univ. Tokyo

Background: In view of the upcoming clinical trials of disease-modifying drugs for Alzheimer’s disease (AD), there is a compelling need for the establishment of a complete set of surrogate biomarkers that reflect and predict the progression of AD, especially conversion from mild cognitive impairment (MCI) to AD. For this purpose, AD neuroimaging initiative (ADNI) is currently being conducted in US, collecting MRI and PET images as well as biological fluids, together with psychometric measures. In concert with this trend, Japanese clinicians and researchers on AD started Japanese ADNI (J-ADNI), which is sponsored by governmental funding bodies (NEDO and MHLW) as well as pharmas, from April 2007.

Research plan: Thirty-eight clinical sites in Japan will conduct a longitudinal study enrolling 300 amnestic MCI individuals, 150 cognitively normal aged controls and 150 early AD patients for 3 (AD: 2) yrs using neuropsychological batteries (100%), 1.5T MRI (100%), FDG-PET (~70%), amyloid imaging (~45%); will also collect biological fluids (blood 100%, CSF ~40%, DNA samples 100%). All the protocols are designed to gain as much compatibility to that of US-ADNI. Takeshi Iwatsubo heads the group as PI with the assistance of core PIs (Clinical: Takashi Asada and Hiroyuki Arai, Neuropsychology: Morihiro Sugishita, MRI: Hiroshi Matsuda, PET: Kengo Ito and Michio Senda, Amyloid PET: Kenji Ishii, Biomarker: Ryozo Kuwano and Hiroyuki Arai, IT: Noriko Sato and Fumio Yamashita).

Timeline and funding: A 5-year research program is being conducted. Participant enrollment: July 2008-March 2011. Study: July 2008-March 2014. Initial analysis: January 2010. Final analysis and report: April 2014. Public funding: grants from NEDO (a foundation of ministry of economy, trade and industry), from ministry of health, labor and welfare (2007-2009, 2010-2012). Funding from pharmas (11 companies as J-ISAB: Astellas, Bristol-Myers Squibb, Daiichi-Sankyo, Dainippon-Sumitomo, Eisai, Eli-Lilly, Merck-Banyu, Pfizer, Shionogi, Takeda, Tanabe-Mitsubishi), 2007-2012.

J-ADNI has so far recruited 460 individuals (152 cognitively normal, 218 MCI, 90 AD) as of December 2010 and the analysis of data is ongoing.

To page top
Copyright Research Association for Biotechnology, All Rights Reserved